Abstract:Abstract Background LKB1 is a protein kinase that is mutated and down-regulated in 20-30% of NSCLC. LKB1 mutations co-occur with KRAS alterations in 7%-10% of NSCLC, resulting in an aggressive phenotype with short survival, and frequent metastases. Because LKB1 activates AMPK, many of the best known functions of LKB1 are attributed to its ability to control metabolic alterations in the cells. However LKB1 also plays an important role in regulating tumor progression, metastasis and angiogenesis, likely as a compensatory strategy to overcome energetic depletion of tumor microenvironment. Bevacizumab, the anti-VEGF antibody improves PFS in NSCLC patients combined with chemotherapy but the benefit is modest and transient and often patients develop resistance. Our laboratory has identified alterations in cell metabolism and in vasculature of LKB1 deficient tumors when compared to LKB1 wild type. These findings may indicate that loss of LKB1 could alter the tumor vasculature in NSCLC. Methods mRNA expression of angiogenesis related genes were analyzed in wild type and LKB1 deficient NSCLC tumors (TCGA). In vitro validation was performed by qPCR and western blot. CD31 IHC was performed to analyze microvasculature density (MVD) in Krasmut and Krasmut LKB1f/f mice tumors. HUVEC tube formation and migration assays were performed with conditioned medium of LKB1 expressing and deficient NSCLC isogeneic cell lines. Xenograft NSCLC models were established via s.c. injection of H460 (LKB1 deficient) and H460 LKB1 (LKB1 expressing) cells in nude mice. Treatment consisting of human and/or mouse bevacizumab and nintedanib were administrated. Tumor volumes were measured and vasculature analysis was performed. Results In vitro HUVEC cells exhibited an increase migration and differences in endothelial network formation when incubated with conditioned medium from LKB1 deficient cells compared to LKB1 expressing cells medium (p<0.05). LKB1 deficient cells upregulated hypoxia and energetic stress related genes (HIF1AN, EGLN1, HIF3A, EPAS1 and CA12) and increased the secretion of angiogenesis related factors (VEGF, IL8, endoglin). IHC analysis of baseline CD31 expression of tumors from Krasmut and Krasmut LKB1f/f mutant mice showed no significant differences in MVD. However, anti-angiogenic therapy significantly inhibited tumor progression in LKB1 expressing xenografts but did not show any therapeutic effect in LKB1 deficient tumors. LKB1 expressing xenografts treated with human or mouse bevacizumab, or the combination of both and nintedanib, resulted in a significant decrease in tumor volume (p<0.05). The blockade of human and mouse VEGF showed an optimal therapeutic effect with approximately 70% reduction of tumor volume (p<0.001). Conclusions LKB1 deficiency may promote resistance to anti-angiogenic therapy by regulating compensatory angiogenic pathways along metabolic adaptations to energetic stress in NSCLC. Citation Format: Irene Guijarro, Alissa Poteete, Chao Yang, Emily Roarty, Monique Nilsson, Huiying Sun, Pan Tong, Edward Chang, Jaime Rodriguez-Canales, Barbara Mino, Edwin Parra, Ignacio Wistuba, Jing Wang, Timothy Heffernan, John V. Heymach. LKB1 loss is associated with resistance to VEGF inhibitors in non-small cell lung cancer (NSCLC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3272.

Liver Kinase B1 (LKB1) Regulates Proliferation and Apoptosis of Non-Small Cell Lung Cancer A549 Cells via Targeting ERK Signaling Pathway

Cytoplasmic Liver Kinase B1 Promotes the Growth of Human Lung Adenocarcinoma by Enhancing Autophagy.

Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer

LKB1 Mutations Enhance Radiosensitivity in Non-Small Cell Lung Cancer Cells by Inducing G2/M Cell Cycle Phase Arrest

Overexpression of the LKB1 Gene Inhibits Lung Carcinoma Cell Proliferation Partly Through Degradation of C-Myc Protein.

Effect of α5β1 Integrin and ERK Signaling Pathway on Non-small Cell Lung Cancer

[Effect of transfection of LKB1 on biological behavior of human lung adenocarcinoma cells].

Reduced Expression of Liver Kinase B1 and Beclin1 is Associated with the Poor Survival of Patients with Non-Small Cell Lung Cancer

Liriopesides B Induces Apoptosis and Cell Cycle Arrest in Human Non‑small Cell Lung Cancer Cells.

Lenvatinib Inhibits AKT/NF-κB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer.

Under-expression of LKB1 is Associated with Enhanced P38-Mapk Signaling in Human Hepatocellular Carcinoma.

LKB1 Gene Inactivation Does Not Sensitize Non-Small Cell Lung Cancer Cells to Mtor Inhibitors in Vitro

LKB1 inhibits proliferation, metastasis and angiogenesis of thyroid cancer by upregulating SIK1

LKB 1 / AMPK / Mtor Signaling Pathway in Non-small-cell Lung Cancer

Suppression of Lung Cancer Cell Invasion by LKB1 is Due to the Downregulation of Tissue Factor and Vascular Endothelial Growth Factor, Partly Dependent on SP1

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment

KLRB1 expression is associated with lung adenocarcinoma prognosis and immune infiltration and regulates lung adenocarcinoma cell proliferation and metastasis through the MAPK/ERK pathway

Influence of Specific Down-Regulation of LKB1 Expression on Invasion and Migration of Hepatoma Cells

Abstract 3272: LKB1 Loss is Associated with Resistance to VEGF Inhibitors in Non-Small Cell Lung Cancer (NSCLC)

Abstract 2150: LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade

Camp/creb-Regulated LINC00473 Marks LKB1-inactivated Lung Cancer and Mediates Tumor Growth